Dosing & Uses
Dosage Forms & Strengths
capsule
- 250mg
Intestinal Amebiasis (E. Histolytica)
25-35 mg/kg/day PO divided q6hr for 5-10 days
Effective in acute and chronic but not extraintestinal
Hepatic Coma (Adjunctive)
4 g PO qDay in divided doses for 5-6 days
Diantomoeba Fragilis
20-30 mg/kg/day PO divided q8hr
Tapeworm (T. saginata/T. solium/D. latum/D. caninum)
11 mg/kg PO divided q15min for 4 doses
Dwarf Tapeworm
45 mg/kg/dose PO qDay for 5-7 days
Cutaneous Leishmaniasis (Orphan)
Treatment of cutaneous leishmaniasis (Old World and New World)
Sponsor
- The Surgeon General, Dept. of the Army; USAMRMC; 504 Scott Street; Ft. Detrick; MD
Dosage Forms & Strengths
capsule
- 250mg
E. Histolytica
25-35 mg/kg/day divided q8hr PO for 7 days OR
750 mg/m²/day divided q6hr PO for 5 days
Dientamoeba Fragilis
25-30 mg/kg/day PO divided q8hr for 7 days
Intestinal Amebiasis
25-35 mg/kg/day PO divided q8hr for 5-10 days
Tapeworm (Hymenolepis nana)
Tapeworm (T. saginata/T. solium/D. latum/D. caninum)
11 mg/kg PO divided q15min for 4 doses
Dwarf Tapeworm
45 mg/kg/dose PO qDay for 5-7 days
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
1-10%
Diarrhea
Abdominal cramps
Nausea
Vomiting
Heartburn
<1%
Headache
Vertigo
Exanthema
Rash
Pruritus
Steatorrhea
Secondary enterocolitis
Eosinophilia
Ototoxicity
Warnings
Contraindications
Hypersensitivity, intestinal obstruction
Cautions
Prolonged treatment may result in fungal or bacterial superinfection
Caution in renal impairment or patients with ulcerative bowel lesions
Pregnancy & Lactation
Pregnancy Category: C
Lactation: does not enter breast milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Aminoglycoside; interferes with bacterial protein synthesis by binding to 30S ribosomal subunits; has antibacterial against pathogenic organisms in the GI tract
Pharmacokinetics
Absorption: Poor
Excretion: Feces (100% as unchanged drug)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
